Claire Provost1, Laura Rozenblum-Beddok2,3, Valérie Nataf2,3, Fatiha Merabtene4, Aurélie Prignon2, Jean-Noël Talbot2,3. 1. Laboratoire d'Imagerie Moléculaire Positonique (LIMP), UMS 28, UPMC - Sorbonne Universités, Paris, France. claire.provost@upmc.fr. 2. Laboratoire d'Imagerie Moléculaire Positonique (LIMP), UMS 28, UPMC - Sorbonne Universités, Paris, France. 3. Service de Médecine Nucléaire et Radiopharmacie, Hôpital Tenon, AP-HP, Paris, France. 4. Plateforme d'Histomorphologie Service d'Anatomie Pathologique, Hôpital Saint Antoine, AP-HP, Paris, France.
Abstract
PURPOSE: The aim of this study was to evaluate positron emission tomography (PET) imaging with [68Ga]NODAGA-c(RGDfK) ([68Ga]RGD), in comparison with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), for early monitoring of the efficacy of an antiangiogenic agent associated or not with chemotherapy, in a mouse model of glioblastoma (GB). PROCEDURES: Mice bearing U87MG human GB cells line were parted into five groups of five mice each. One group was imaged at baseline before the treatment phase; another group was treated with bevacizumab (BVZ), another group with temozolomide (TMZ), another group with both agents, and the last one was the control group. Tumors growth and biological properties were evaluated by caliper measurements and PET imaging at three time points (baseline, during treatment t1 = 4-6 days and t2 = 10-12 days). At the end of the study, tumors were counted and analyzed by immunohistochemistry (CD31 to evaluate microvessel density). RESULTS: The tumor volume assessed by caliper measurements was significantly greater at t1 in the control group than in the TMZ + BVZ-treated group or in the BVZ-treated group. At t2, tumor volume of all treated groups was significantly smaller than that of the control group. [18F]FDG PET failed to reflect this efficacy of treatment. In contrast, at t1, the [68Ga]RGD tumor uptake was concordant with tumor growth in controls and in treated groups. At t2, a significant increase in tumor uptake of [68Ga]RGD vs. t1 was only observed in the TMZ-treated group, reflecting a lack of angiogenesis inhibition, whereas TMZ + BVZ resulted in a dramatic tumor arrest, reduction in microvessel density and stable tumor [68Ga]RGD uptake. CONCLUSIONS: [68Ga]RGD is a useful PET agent for in vivo angiogenesis imaging and can be useful for monitoring antiangiogenic treatment associated or not with chemotherapy.
PURPOSE: The aim of this study was to evaluate positron emission tomography (PET) imaging with [68Ga]NODAGA-c(RGDfK) ([68Ga]RGD), in comparison with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), for early monitoring of the efficacy of an antiangiogenic agent associated or not with chemotherapy, in a mouse model of glioblastoma (GB). PROCEDURES: Mice bearing U87MG human GB cells line were parted into five groups of five mice each. One group was imaged at baseline before the treatment phase; another group was treated with bevacizumab (BVZ), another group with temozolomide (TMZ), another group with both agents, and the last one was the control group. Tumors growth and biological properties were evaluated by caliper measurements and PET imaging at three time points (baseline, during treatment t1 = 4-6 days and t2 = 10-12 days). At the end of the study, tumors were counted and analyzed by immunohistochemistry (CD31 to evaluate microvessel density). RESULTS: The tumor volume assessed by caliper measurements was significantly greater at t1 in the control group than in the TMZ + BVZ-treated group or in the BVZ-treated group. At t2, tumor volume of all treated groups was significantly smaller than that of the control group. [18F]FDG PET failed to reflect this efficacy of treatment. In contrast, at t1, the [68Ga]RGD tumor uptake was concordant with tumor growth in controls and in treated groups. At t2, a significant increase in tumor uptake of [68Ga]RGD vs. t1 was only observed in the TMZ-treated group, reflecting a lack of angiogenesis inhibition, whereas TMZ + BVZ resulted in a dramatic tumor arrest, reduction in microvessel density and stable tumor [68Ga]RGD uptake. CONCLUSIONS: [68Ga]RGD is a useful PET agent for in vivo angiogenesis imaging and can be useful for monitoring antiangiogenic treatment associated or not with chemotherapy.
Authors: Teri Nguyen Kreisl; Perry Smith; Joohee Sul; Carlos Salgado; Fabio M Iwamoto; Joanna H Shih; Howard A Fine Journal: J Neurooncol Date: 2012-10-20 Impact factor: 4.130
Authors: Jianzhong Huang; Jason S Frischer; Anna Serur; Angela Kadenhe; Akiko Yokoi; Kimberly W McCrudden; Tamara New; Kathleen O'Toole; Stephanie Zabski; John S Rudge; Jocelyn Holash; George D Yancopoulos; Darrell J Yamashiro; Jessica J Kandel Journal: Proc Natl Acad Sci U S A Date: 2003-06-12 Impact factor: 11.205
Authors: Andreas Clemmensen; Adam E Hansen; Pernille Holst; Christina Schøier; Sissel Bisgaard; Helle H Johannesen; Jan Henrik Ardenkjær-Larsen; Annemarie T Kristensen; Andreas Kjaer Journal: Eur J Nucl Med Mol Imaging Date: 2020-07-03 Impact factor: 9.236
Authors: Keshav Datta; Mette H Lauritzen; Milton Merchant; Taichang Jang; Shie-Chau Liu; Ralph Hurd; Lawrence Recht; Daniel M Spielman Journal: PLoS One Date: 2019-12-12 Impact factor: 3.240